Three-year's changes in glucose tolerance status in the Bellville South cohort: Rates and phenotypes associated with progression

Diabetes Research and Clinical Practice

Volumn 99, Issue 2, 2013, Pages 223-230

  Matsha, T E ^a   Soita, D J ^a   Hassan, M S ^a,b   Hon, G M ^a   Yako, Y Y ^b   Kengne, A P ^c   Erasmus, R T ^b  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Diabetes mellitus; Glucose tolerance; Metabolic syndrome; Progression; Risk factors; South Africa

Indexed keywords

COTININE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; GLUCOSE TOLERANCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PREDICTION; RISK FACTOR; SOUTH AFRICA; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SOUTH AFRICA;

EID: 84876736464     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.10.018     Document Type: Article

References (30)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Klein B.E., Klein R., Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002, 25:1790-1794.
3. Levitt N.S., Katzenellenbogen J.M., Bradshaw D., Hoffman M.N., Bonnici F. The prevalence and identification of risk factors for NIDDM in urban Africans in Cape Town, South Africa. Diabetes Care 1993, 16:601-607.
4. Erasmus R.T., Blanco Blanco E., Okesina A.B., Matsha T., Gqweta Z., Mesa J.A. Prevalence of diabetes mellitus and impaired glucose tolerance in factory workers from Transkei, South Africa. S Afr Med J 2001, 91:157-160.
5. Motala A.A., Pirie F.J., Gouws E., Amod A., Omar M.A. High incidence of Type 2 diabetes mellitus in South African Indians: a 10-year follow-up study. Diabet Med 2003, 20:23-30.
6. Zemlin A.E., Matsha T.E., Hassan M.S., Erasmus R.T. HbA1c of 6.5% to diagnose diabetes mellitus - does it work for us? - the Bellville South Africa study. PLoS ONE 2011, 6:e22558.
7. Matsha T.E., Hassan M.S., Kidd M., Erasmus R.T. The 30-year cardiovascular risk profile of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia: the Bellville, South Africa pilot study. Cardiovasc J Afr 2012, 23:5-11.
8. Gillies C.L., Abrams K.R., Lambert P.C., Cooper N.J., Sutton A.J., Hsu R.T., et al. Pharmacological lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review meta-analysis. BMJ 2007, 334:299.
9. de Wit E., Delport W., Rugamika C.E., Meintjes A., Möller M., van Helden P.D., et al. Genome-wide analysis of the structure of the South African coloured population in the Western Cape. Hum Genet 2010, 128:145-153.
10. Chalmers J., MacMahon S., Mancia G., Whitworth J., Beilin L., Hansson L., et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999, 21:1009-1060.
11. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
12. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
13. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006, 6:33.
14. Gómez-Ambrosi J., Silva C., Galofré J.C., Escalada J., Santos S., Millán D., et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) 2012, 36:286-294.
15. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
16. Sattar N., McConnachie A., Shaper A.G., Blauw G.J., Buckley B.M., de Craen A.J., et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927-1935.
17. Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
18. Leite S.A., Anderson R.L., Kendall D.M., Monk A.M., Bergenstal R.M. A1C predicts type 2 diabetes and impaired glucose tolerance in a population at risk: the community diabetes prevention project. Diabetol Metab Syndr 2009, 1:5.
19. International Expert, Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
20. Report of a World Health Organization Consultation Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011, 93:299-309.
21. Miyazaki M., Kubo M., Kiyohara Y., Okubo K., Nakamura H., Fujisawa K., et al. Hisayamastudy comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama Study. Diabetologia 2004, 47:1411-1415.
22. Saudek C.D., Herman W.H., Sacks D.B., Bergenstal R.M., Edelman D., Davidson M.B. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008, 93:2447-2453.
23. Alberti K.G.M.M., Zimmet P., Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med 2007, 24:451-463.
24. Motala A.A., Omar M.A., Gouws E. High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance. Diabetes 1993, 42:556-563.
25. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., Mott D.M., Bennett P.H. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1988, 319:1500-1506.
26. King H., Zimmet P., Raper L.R., Balkau B. The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a six-year follow-up study. Diabetologia 1984, 26:39-43.
27. Goldberg R.B., Temprosa M., Haffner S., Orchard T.J., Ratner R.E., Fowler S.E., et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the diabetes prevention program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009, 32:726-732.
28. Hamman R.F., Wing R.R., Edelstein S.L., Lachin J.M., Bray G.A., Delahanty L., et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102-2107.
29. Riley P., Sudarshi D., Johal M., Benedict A., Panteli J., Crook M., et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract 2008, 62:374-381.
30. Hickman I.J., Jonsson J.R., Prins J.B., Ash S., Purdie D.M., Clouston A.D., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-419.